The Metabolic (Dysfunction) Associated Fatty Liver Disease Consortium (MAIDEN) was founded in December 2022 as the official body to represent APASL on any matters related to fatty liver disease. The consortium comprises 146 key opinion leaders from 22 countries/administrative regions in the Asia Pacific region. The intent of the consortium is to bring together clinicians, researchers, and patient representatives to tackle the burden of MAFLD. MAIDEN will run topical conferences, webinars, and related educational events. Please, see the website for more information https://maiden-apasl.com